Please ensure Javascript is enabled for purposes of website accessibility

Human Genome rejects GlaxoSmithKline’s $2.59B bid (access required)

The decision by Rockville-based biotech drugmaker Human Genome Sciences Inc. to reject an unsolicited $2.59 billion takeover bid Thursday may increase the eventual sale price of the company, analysts said. The question is by how much. “For the most part, we think it’s a fair offer,” said Lauren Migliore, an equity analyst with Chicago-based Morningstar. “The premium ...